Results 1 to 10 of about 249,886 (308)

Effects of Immunomodulatory Therapy on the Skin Barrier Function in Patients with Psoriasis Vulgaris [PDF]

open access: yesMedicina
Background and Objectives: Psoriasis vulgaris features epidermal barrier dysfunction. Materials and Methods: Barrier function changes were prospectively evaluated over 12 weeks during TNF-α inhibition with adalimumab, along with concurrent changes in ...
Anete Mālkalne   +4 more
doaj   +2 more sources

Immunopathogenesis and immunomodulatory therapy for myocarditis. [PDF]

open access: yesSci China Life Sci, 2023
Myocarditis is an inflammatory cardiac disease characterized by the destruction of myocardial cells, infiltration of interstitial inflammatory cells, and fibrosis, and is becoming a major public health concern. The aetiology of myocarditis continues to broaden as new pathogens and drugs emerge.
He W   +6 more
europepmc   +3 more sources

Immunomodulatory Therapy for Ischemic Heart Disease. [PDF]

open access: yesCirculation
Ischemic heart disease is a leading cause of death worldwide, manifested clinically as myocardial infarction (and ischemic cardiomyopathy. Presently, there exists a notable scarcity of efficient interventions to restore cardiac function after myocardial infarction.
Zhao X   +4 more
europepmc   +4 more sources

Immunomodulatory Therapy for Rasmussen Syndrome

open access: yesPediatric Neurology Briefs, 2013
Investigators from the National Epilepsy Center, Shizuoka, Gifu University, Tokyo Women’s Medical University, National Center of Neurology and Psychiatry, and Okayama University School of Medicine, Japan, examined seizure, cognitive, and motor outcomes ...
J Gordon Millichap
doaj   +3 more sources

Immunomodulatory therapy in ENT practice

open access: yesМедицинский совет, 2016
Area Moscow’s regional research clinical institute n.a. M.F. Vladimirskiy Abstract. The article analyzes the experience of application of the immunomodulator Polyoxidonium in patients with respiratory diseases.
D. M. Mustafaev, V. I. Egorov
doaj   +3 more sources

Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study

open access: yesMedicina, 2021
Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice.
Maria Livia Del Giudice   +13 more
doaj   +1 more source

The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

open access: yeseJHaem, 2023
Pomalidomide‐dexamethasone (Pd) has been a standard care treatment for relapsed and refractory multiple myeloma since 2013. However, the outcomes of Pd after exposure to CD38 antibodies are not known.
Agoston Gyula Szabo   +11 more
doaj   +1 more source

In dogs with atopic skin disease, is lokivetmab more effective than oclacitinib in reducing the score of a recognised scoring system?

open access: yesVeterinary Evidence, 2022
PICO question In dogs with atopic skin disease, is lokivetmab more effective than oclacitinib in reducing the Canine Atopic Dermatitis Lesion Index score (or some other recognised scoring system)?
Bonnie Yuan Tone Cheung
doaj   +1 more source

Treatment Approaches for Atypical CIDP

open access: yesFrontiers in Neurology, 2021
The variants of chronic inflammatory demyelinating polyneuropathy (CIDP) differ not just in their clinical, pathological and electrophysiological characteristics, but often in their indifferent response to conventional immunosuppressive agents which are ...
Deepak Menon   +2 more
doaj   +1 more source

Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (focus) initiative [PDF]

open access: yes, 2018
Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics.
Acharya, Nisha   +150 more
core   +4 more sources

Home - About - Disclaimer - Privacy